A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2019
At a glance
- Drugs Sonidegib (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Jun 2019 Trial has been completed in France, according to European Clinical Trials Database record.
- 08 Feb 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 13 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.